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The aim of this study was to evaluate two important aspects of patent applications of crystalline forms 
of drugs: (i) the physicochemical characterization of the crystalline forms; and (ii) the procedure for 
preparing crystals of the blockbuster drug clopidogrel. To this end, searches were conducted using 
online patent databases. The results showed that: (i) the majority of patent applications for clopidogrel 
crystalline forms failed to comply with proposed Brazilian Patent Office guidelines. This was primarily 
due to insufficient number of analytical techniques evaluating the crystalline phase. In addition, some 
patent applications lacked assessment of chemical/crystallography purity; (ii) use of more than two 
analytical techniques is important; and (iii) the crystallization procedure for clopidogrel bisulfate form 
II were irreproducible based on the procedure given in the patent application.
Uniterms: Clopidogrel/crystalline forms/physicochemical characterization. Clopidogrel/crystalline 
forms/patents. Polymorphism.
Este trabalho tem como objetivo avaliar dois aspectos importantes em um pedido de patente de formas 
cristalinas de fármacos: (i) caracterização físico-química das formas cristalinas e (ii)o procedimento 
de preparo da forma II do fármaco clopidogrel, um blockbuster de vendas. Realizaram-se buscas em 
bancos de dados patentários on line. Os resultados mostraram que (i) a maioria dos pedidos de patente de 
formas cristalinas do clopidogrel não se adequam com proposta do INPI devido ao número insuficiente 
de técnicas analíticas utilizadas na caracterização da fase cristalina. Ainda, em alguns pedidos de patente 
não há a presença da avaliação da pureza química/cristalográfica; (ii) a importância de se utilizar mais de 
duas técnicas de avaliação e (iii) que não foi possível a reprodução da cristalização com o procedimento 
apresentado no pedido de patente.
Unitermos: Clopidogrel/forma cristalina/caracterização físico-química. Clopidogrel/forma cristalina/
patentes. Polimorfismo.
INTRODUCTION
Patents are one of the most effective tools for 
researchers, whether individuals or corporations, to 
protect their investments and secure temporary marketing 
exclusivity of an invention. Currently, the pharmaceutical 
industry is one of the most frequent users of the international 
patent system (Correa, 2007; Cabri et al., 2006). This has 
been especially true after the signing of the Agreement 
on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) on April 15th 1994, during the last meeting of the 
General Agreement on Tariffs and Trade (GATT) study 
group. This agreement established minimum levels of 
protection for inventions across all technology fields for 
signatories of the World Trade Organization (WTO).
With the decline in the number of patent applications 
for new molecular entities, the pharmaceutical industry 
increasingly relies on so-called “incremental innovations”, 
i.e., requests for privileges of secondary issues regarding 
the initial invention (usually molecular entities). This is 
especially the case for true polymorphs, amorphous and 
solvatomorphic forms of a known compound already 
revealed in the prior art. This kind of patent applications 
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can lead to an extension of patent protection, which is 
known as evergreening, a widely used business strategy 
(Bansal et al, 2009; Plaza De Avila, 2007; Mitssuchi, 2009; 
Correa, 2006; Burdon, Sloper, 2003; Lerma, 2007).
One type of incremental innovation in the pharma-
ceutical area involves the discovery of amorphous 
and/or polymorphic forms of known compounds. 
Polymorphism is a property displayed by some organic 
or inorganic molecules that can exist in multiple crystal 
forms with different arrangements / conformations of 
their respective crystal lattices (Grant, 1999). Molecular 
entities demonstrate two kinds of crystalline systems: 
the single-component (anhydrous/non solvated forms) 
and multi-component (solvatomorphs, salts and co-
crystals). Although the Food and Drug Administration 
(FDA) states that co-crystals are a type of Active 
Pharmaceutical Ingredient (API)-excipient blend, these 
systems may converge and produce different polymorphic 
forms (Aitipamula et al, 2012; FDA, 2013). Since 
polymorphs have different molecular arrangements, they 
carry different energies, which affect various important 
physicochemical properties such as reactivity, solubility, 
compressibility and flow (Vippagunta, Brittain, Grant, 
2001). It is generally accepted that when developing a 
pharmaceutical form, the lower energy crystalline lattice 
is the most stable form and helps to avoid degradation 
and polymorphic transitions. However, there are some 
exceptions in which a less stable form is used for its 
increased solubility (Singhal, Curatolo, 2004).
The physicochemical characterization of molecules 
in the phase is common practice in the state of the art 
and it is currently acknowledged that various analytical 
techniques should be used concomitantly for the 
identification of polymorphic forms (Vippagunta, Brittain, 
Grant, 2001; Yu, Reutzel, Stepheson, 1998; Byrn et 
al., 1995; Suryanarayanan, 1995; Brittain, 1995). The 
literature unanimously describes single crystal X-ray 
diffraction (SCXRD) as the primary analytical technique 
used for the physical characterization of crystalline 
phases. This technique yields important molecular 
details: including unit cell parameters, molecular density 
and conformation. However, powder X-ray diffraction 
(PXRD), solid phase spectroscopy (Infrared spectroscopy 
- IR, with or without Fourier transformation (FTIR), 
Raman spectroscopy, 13carbon solid state nuclear magnetic 
resonance - 13CSSRMN), thermal analysis (Differential 
scanning calorimetry - DSC, Thermogravimetric Analysis 
- TGA, among others) and microscopy techniques also 
assist in providing important information on the nature 
of polymorphic and amorphous molecules (Vippagunta, 
Brittain, Grant, 2001).
Recently, the Brazilian National Institute of 
Industrial Property (INPI) released a draft document 
entitled Proposed Guidelines for Examination of Patent 
Applications for New Polymorphic Forms, for public 
consideration. In the document, the appropriate analytical 
techniques for the characterization of a polymorphic 
form in a patent application were outlined: single 
Crystal X-Ray Diffraction (SCXRD), Powder X-Ray 
Diffraction (PXRD), Carbon Solid State Nuclear Magnetic 
Resonance Spectroscopy (13CSSRMN), infrared or 
Fourier Transform Spectroscopy (IR; FT-IR), RAMAN 
Spectroscopy, “hot stage” electron microscopy and 
thermal analysis: Differential Scanning Calorimetry -DSC, 
Thermogravimetric Analysis - TGA and Differential 
Thermal Analysis- DTA.
By evaluating the guidelines proposed by INPI, 
three decreasing “levels” of acceptance for crystal 
characterization can be discriminated: 1 – The use of single 
crystal X-ray diffraction (from the text of the proposal: 
in the case of a single crystal of the chemical, single 
crystal XRD is sufficient for the perfect characterization 
of crystalline structure); 2 - in the absence of “1”, 
powder X-ray diffraction should be employed with the 
Miller indices of the interplanar spacings (or interplanar 
spacings calculated from Miller indices), the Bragg´s 
angle reflection and the relative intensities of at least 20 
reflections (from the text of the proposal: in the absence of 
a single crystal of the chemical, the powder XRD method 
with indexing is the preferred technique that should be 
used. The following criteria should be used including: the 
Miller indices of interplanar distances, Bragg´s angles 
and the relative intensities of at least 20 reflections beyond 
the unit cell parameters); and for 3 - in cases of non-
submission of these parameters, powder X-ray diffraction 
must be accompanied by at least two analytical techniques 
along with an evaluation of sample purity (as quoted 
directly from the proposal text: where indexing is not 
provided, it is necessary to present the other parameters 
described and complementation technique of powder 
XRD method with at least two other analysis methods, 
(minimum of two), in addition to proving the purity of the 
sample) (INPI, 2010).
Patents of polymorphs in the pharmaceutical field 
have been the subject of debate in regards to academic, 
scientific and legal views based on the premise that, in 
developing countries, the granting of incremental patents 
in the pharmaceutical area results in reduced access to 
medicines (Correa, 2007; Cabri et al., 2006; Plaza De 
Avila, 2007; Mitssuchi, 2009; Correa, 2006; Burdon, 
Sloper, 2003; Lerma, 2007). The WTO discussed the 
matter in 2001 and prepared a document entitled the 
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“Doha Declaration”, which was actually a letter of 
intent that provides for the implementation of all the 
TRIPS flexibilities related to protecting public health in 
developing countries in the political sphere (WTO, 2001). 
In the Polymorphic field, it is hard to determine whether 
these kind of patents are genuinely derived from the 
intellectual efforts of the researcher and solve a problem 
of prior art, or are merely legal tools used as a mechanism 
to indirectly extend a previously granted patent (the patent 
of a molecule), and, ultimately, hinder the entry of generic 
drugs onto the market.
According to the Industrial Property Law (Law 
9279/96 of 14 May 1996 - LPI) (Brazil, 1996), the most 
important articles for technical examination by the INPI 
of a patent application are the patentability requirements 
- novelty (Art. 11), inventive step (Art. 13) and industrial 
application (Art. 15), and also the conditions of the patent 
application, in particular concerning the sufficiency of 
disclosure of description (art. 24) and clarity of claims 
(Art. 25). Among these articles, special attention should 
be devoted to Articles 11 and 24, since they are essential 
for differentiation of the prior art and reproduction by 
others, respectively. According to the LPI, the invention 
and utility model are considered new when they are not 
included in the prior art. Concerning the sufficiency of 
disclosure, the description should clearly and adequately 
describe the object, to enable reproduction by those 
skilled in the art and indicate, where appropriate, the best 
execution method.
Therefore, it is understood that the patent application 
must provide accurate and sufficient data on the subject 
for examination by a patent examiner, so that it can be 
differentiated from the state of the art. Moreover, sufficient 
disclosure should be considered essential for achieving 
one of the pillars of the patent system. The technology 
involved in the invention must be accessible to the general 
public. Thus, the importance of proper presentation of 
technical data in patent applications of polymorphs of 
drugs is emphasized here.
Clopidogrel (methyl (+)-S-α-(2-chlorophenyl-
4,5,6,7-tetrahydrothiene[3,2-c] pyridine-5-acetate) is 
a potent antiplatelet and antithrombotic drug, that was 
released onto the market after a clinical study demonstrated 
that it had superior efficacy in preventing thrombotic 
events when compared to aspirin (myocardial infarction 
and stroke number) (Clement, 1996). Clopidogrel is an 
ADP binding inhibitor of platelets via P2Y12 (Herbert, 
Savi, 2003). This drug has two enantiomers and the 
active form is S-(+)-clopidogrel and requires hepatic 
biotransformation to activate its pharmacological activity 
(Clement, 1996). Clopidogrel is currently marketed as its 
bisulfate salt (Plavix®) (Figure 1) in 2008 had worldwide 
sales worth around 2.616 billion euros (SANOFI, 2012).
The patent applications of crystalline clopidogrel 
were investigated and analytical techniques for charac-
terization of the crystalline phase assessed according to 
the guidelines proposed by the INPI. Clopidogrel bisulfate, 
forms I and II, was obtained from commercial samples 
and characterized according to the proposed guidelines. 
Furthermore, attempts to reproduce the preparation of 
clopidogrel bisulfate form II were undertaken, as described 
in the PI9911219 Brazilian patent application (Bousquet, 
Castro, Saint-Germain, 2001). Patent applications of 
amorphous forms were included in the searches; however, 
these results were not used for assessing the analytical 
techniques.
METHODOLOGY
Search
The search strategies and experimental methods 
utilized in this work consisted of: (i) identification of patent 
applications of the clopidogrel compound (the first patent 
application disclosing clopidogrel); (ii) identification 
and evaluation of patent applications pertaining to the 
polymorphic forms of clopidogrel. For the search (i), 
the Food and Drug Administration site (FDA, 2012) was 
used, while for search (ii) the European Patent Office 
(European Patent Office - EPO) (Espacenet, 2012), INPI 
site (INPI, 2012) and database ISI web of Knowledge - 
Derwent Innovations Index (Derwent, 2012) were used. 
These searches were carried out using keywords and by 
subsequent manual mining of patent applications. The 
selected patent applications were evaluated to determine 
whether they fulfilled the acceptance criteria outlined in 
the proposed INPI guidelines. In this study, the profile of 
applicants and analytical techniques used to characterize 
the crystalline phase of the crystalline/polymorphic 
clopidogrel forms were investigated.
FIGURE 1 – Chemical structure of clopidogrel bisulfate 
(hydrogenosulfate). Adapted from Bousquet, Castro, Saint-
Germain, 1999.
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Characterization of clopidogrel bisulfate 
polymorphic forms I and II and preparation of 
form II using the procedure described in the 
Brazilian patent application PI9911219
Reagents and chromatography parameters
The amorphous clopidogrel free base and forms I 
and II were purchased from Zhejiang Jiuzhou Pharma. 
All the reagents utilized were of USP grade. The purity of 
samples used in the characterization techniques and the 
experimental procedure to produce form II of clopidogrel 
bisulfate was evaluated using a Shimadzu VP LC-10A VP 
chromatograph. The chromatographic conditions used 
for the purity analysis were: C18 column 150 x 46 x 5 
microns, UV detection at 220 nm, flow 1.0 mL / min with 
a mobile phase of Phosphate buffer/ Acetonitrile in water 
75/25 (USP, 2012).
Analytical techniques for characterization of the 
crystalline phase 
To characterize the polymorphic forms I and II of 
the commercial clopidogrel bisulfate, PXRD, IR and DSC 
methods were employed. For PXRD, the sample was 
finely divided and analyzed on a Rigaku Miniflex X-Ray 
diffractometer operated at 40 KV and 30 mA. The angle 
of diffraction range 2ө was 2 to 60 at room temperature, 
and the X-ray source was CuKα radiation. The IR was 
performed using a Shimadzu Prestige A210045-21 
spectrophotometer with KBr pellets 1.0% w/w and an 
absorption region between 4000 and 400 cm-1. DSC was 
performed using a Shimadzu DSC 60 with a flow rate of 
50mL/min N2 and a heating rate of 10 °C/min in the range 
of 25 to 350 °C.
With regards to the experimental procedures used 
to obtain form II of Clopidogrel bisulfate, the instructions 
for PI9911219 filed by Sanofi Synthelabo were used. All 
reagents used for crystallization were of HPLC grade. The 
crystallization procedure was performed as follows: (i) – 
solubilization of the free base of the drug in acetone P.A. 
to produce the starting material; (ii); treatment of the free 
base with 80% aqueous H2SO4 v/v, partial concentration 
and cooling of the resultant mixture; (iii) – removal of the 
solid material (referred to as form I); (iv) form II appears 
spontaneously from the remaining liquid of interest after a 
waiting period of 3-6 months and temperature not <40 oC. 
Variation in the process reflects only the changes in the 
concentration of the aqueous sulfuric acid used (96% v/v 
instead of 80% v/v).
RESULTS
Search and evaluation of patent applications of 
crystalline/polymorphic forms of clopidogrel
The search strategy used to identify the first patent 
application of clopidogrel consisted of use of the term 
“Clopidogrel” as the keyword on the FDA site, orange 
book section (FDA, 2012). The oldest patent application 
of a currently US marketed product was the US patent 
application US4847265 (Badorc, Fréhel, 1989). In the EPO 
database, searching for the US4847265 family led to the 
collection of some data from the disclosed/claimed subject 
matter in the original patent application (first application 
filed on the same priority date - FR2612929) (Badorc, 
Fréhel, 1988). In this application, no drug polymorphs 
were mentioned. The search syntaxes used for this study 
TABLE I – Search syntax used in the databases
Descriptors INPI Database EPO Patent database Derwent Innovations Index 
Search parameters Advanced 
Search 1-title; Search 
2-summary
Advanced 
Field of search “title or 
summary” field
Advanced 
Entire text search 
Chemical section
Key words and 
Boolean operators
Search syntax:  
Clopidogrel AND 
(polymorph* OR crystal* or 
form* OR thermodynamics* 
OR solvate* OR hydrate * 
OR amorph*)
Search syntax:  
Clopidogrel AND 
(polymorph* OR crystal* OR 
form* OR thermodynamics* 
OR Solvate* OR hydrate* 
OR amorph*)
Search syntax: 
Search 1: Clopidogrel 
Search 2: search 1 AND (Polymorph* 
OR Crystal* OR form OR 
Thermodynamics* OR Solvate* OR 
Hydrate* OR Amorph*);  
Search 2 refined for the 
Pharmacology and Pharmacy fields
* - truncation operator.
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TABLE II – Quantitative results of clopidogrel polymorphic 
patent applications
Database
Number of 
patents after 
search
Number of 
patents after 
review
Final list after 
mining
EPO 204 24
DERWENT 426 17 24
INPI 24 2
are summarized in Table I. The patent applications 
retrieved were manually reviewed (without the help of 
text mining software) in order to remove documents that 
did not include crystalline/polymorphic forms or that were 
from the same family, as well as duplicates (by virtue of 
two searches conducted). Primary results also included the 
patent applications of the amorphous forms of clopidogrel.
A total of 204 documents were found in the EPO, 
426 in Derwent and 24 in the INPI database (09 on title and 
13 on summary searches). The results are summarized in 
Table II. The patent applications excluded concerned the 
pharmaceutical compositions of clopidogrel, preparation 
of clopidogrel polymorphs and patent applications 
outlining new treatment methods. All the documents found 
on the Derwent database were also present in the EPO 
database and all the documents found on the “title” search 
field in the INPI database were again retrieved when the 
“summary” search was performed.
These results show that the number of patent 
applications retrieved by the search syntax in the Derwent 
database was higher than those obtained for the EPO 
database. However, after mining the contents, the number 
of patent applications for the crystalline/polymorphic 
forms was found to be higher in the EPO patent database 
compared to the Derwent database. These results showed 
that a search of the patent database using keywords returns 
a very large number of patent applications that do not 
involve the matter under assessment. This is because the 
keywords used may figure in many kinds of clopidogrel 
patent applications – for example, formulations, analogues 
and use. However, these broad searches were necessary 
to retrieve the greatest number of applications possible, 
particularly due to the fact that in many cases the titles/
abstract of the patent applications do not clearly disclose 
the patent matter. For example, this can be seen in the 
patent applications WO2004026879A1 (Cipla Ltd.) (Rao, 
Kankan, 2004), WO2005080890A1 (Siegfried Generics) 
(Weber, Levis, Ly, 2005), and WO2008034912A2 
(KrkaTovernaZdravil) (Simonic et al., 2008).
Difficulties were encountered retrieving all of the 
original texts of the patent applications. Therefore, in most 
cases the equivalent WO filings (by the Patent Cooperation 
Treaty – PCT - filings) were used for evaluation purposes. 
Applications not filed via PCT were an exception to this 
search method, where in this case the original application 
or some other equivalent online application was used. 
Table III summarizes all of the patent applications 
retrieved in this study. Of the 24 patent applications 
retrieved after mining, there were 03 for which it was only 
possible to retrieve basic bibliographic data such as title, 
applicant and the priority date (Piechaczek et al., 2004; 
Ho et al., 2009a, b).
The results showed that a large number of pharma-
ceutical companies are primarily developing polymorphs 
of bisulfate, hydrobromide and hydrochloride salts of 
S-(+)-clopidogrel, which clearly indicates the search for 
technological alternatives to the free base and salt of the 
initially synthesized bisulfate. Of the sixteen different 
applicants, only the Instytut Farmaceutyczny was not 
a pharmaceutical company. There was a wide range of 
applicant nationalities, with representatives from the 
United States of America (Ivax Corporation), Europe (e.g. 
Sanofi-Aventis, Ratiopharm GmbH, Zentiva, Generics 
Limited, Sanofi-Synthelabo, Adamed SP ZOO among 
others), India (Heterodrugs Ltd., Cadila Healthcare Ltd., 
Cipla Ltd., Ranbaxy Lab Ltd, SK Chemicals Ltd.) and 
Israel (Teva Pharmaceuticals).
Another interesting finding is that only 2 of 
the applicants are listed in the 2011 global executive 
pharmaceutical ranking prepared by the Executive 
Pharmaceutical Consultant: Sanofi-Aventis (3rd) and Teva 
Pharmaceuticals (12th) (Pharmaexec.com, 2012). This 
demonstrates that investment in incremental inventions 
is a research/market strategy in both big pharma and 
generic-drug companies. For Clopidogrel, most applicants 
in Europe and Asia are generics manufacturers, which 
suggests that they work with the same marketing strategy, 
i.e., the development of new crystalline forms (plus various 
new salts and crystalline forms) of a known blockbuster 
drug. From the data depicted in Figure 2, it can be seen 
that India has the largest number of filings, followed by 
France (headquarters of Sanofi) and Israel.
After evaluating the claimed matter present in 
patent applications, it became clear that huge effort has 
been invested in order to obtain several crystalline salts in 
addition to the drug and its polymorphs before expiration 
of the clopidogrel bisulfate molecule patent. Therefore, 
several pharmaceutical companies, regardless of their 
business model, are investing in obtaining new crystalline 
forms of clopidogrel bisulfate. This also extends to the 
L. M. Lira, A. L. Lourenço, G. F. Neves, V. P. Sousa, C. R. Rodrigues, L. M. Cabral234
TABLE III – Patent applications for clopidogrel polymorphs retrieved
Patent Application Priority date Applicant Principal Claimed Matter
WO9965915A1 (Bousquet, Castro, 
Saint-Germain, op cit)
15/06/1998 Sanofi- Synthelabo Clopidogrel bisulfate form II
WO03051362A2 (Lifshitz-Liron et al, 
2003)
18/12/2001 Teva Pharmaceuticals Clopidogrel bisulfate forms III, IV, V and VI; 
amorphous clopidogrel bisulfate.
WO03066637A1 (Kótay Nagy et al., 
2003)
06/02/2002 Egys 
Gyogyszervegyeszet 
Gyar.
Clopidogrel hydrochloride, forms I and II
PL355514A1 (Piechaczek et al., 2004, 
op cit)
14/08/2002 Instytut 
Farmaceutyczny.
No data retrieved
WO2004026879A1 (Rao, Kankan, op 
cit)
19/09/2002 Cipla Ltd. Amorphous clopidogrel bisulfate; complex 
with dissolution enhancer
WO2004052966A1 (Narasa et al., 
2004)
09/12/2002 Heterodrugs Ltd. Clopidogrel bisulfate form III
WO2004081015A1 (Parthasaradhi et 
al., 2004)
10/03/2003 Heterodrugs Ltd. Amorphous clopidogrel bisulfate
WO2004081016A1 (Lohray et al, 
2004)
12/03/2003 Cadila Healthcare Ltd. Amorphous clopidogrel bisulfate and mixtures 
with forms I and II
WO2005026174A1 (Arul, et al, 2007) 11/09/2003 Generics Limited Clopidogrel hydrobromide forms 1, 2 and 3
CZ295386B6 (Hajicek, Pihera, 
Stepnkova, 2005b)
13/01/2004 Zentiva Clopidogrel hydrobromide form II
WO2005068471A1 (Hajicek, Pihera, 
Stepnkova, 2005a)
13/01/2004 Zentiva Clopidogrel hydrobromide forms I, II and III 
WO2005080890A1 (Weber, Levis, Ly, 
op cit)
24/02/2004 Siegfried Generics Int. 
Ag.
Clopidogrel hydrobromide forms A, B, C, D, 
E and F. Clopidogrel napsylate forms A and B 
WO2005117866A1 (Kaznakov, 
Veverkova, Veverka, 2005)
01/06/2004 Ivax Corporation Clopidogrel hydrochloride amorphous form 
WO2006034451A2 (Finkelstein, 
Arohrime, Tessler, 2006)
21/09/2004 Teva Pharmaceuticals Clopidogrel hydrobromide Forms I, II, III, IV, 
V, VI, VII, VIII, IX and X
EP1674468A1 (Jetti, Gersser, 2006) 21/12/2004 Ratiopharm GMBH. Clopidogrel hydrobromide forms A, B, C, D 
and E; Clopidogrel hydrobromide monohydrate 
forms Hy-1 and Hy-2 
WO2005103058A1 (Lorimer, Ng, 
2005a)
20/04/04 Sanofi Aventis Co. Clopidogrel hydrobromide forms B, C and D
WO2005103059A1 (Lorimer, Ng, 
2005b)
20/04/04 Sanofi Aventis Co. Several polymorphs and hydrates of clopidogrel 
1,5-naphtalenedisulfonate
WO200702096A2 (Gangakhedkar, 
2007)
05/09/2005 Ranbaxy Lab. Ltd. Clopidogrel hydrochloride form III 
WO2008034912A2 (Simonic et al., 
2008)
22/09/2006 Krka Tovarna Zdravil 
DD novo.
Several clopidogrel camphor-10-sulfonate 
forms; Clopidogrel bisulfate form I; Clopidogrel 
hydrochloride form
EP1903046A1 (Majka et al., 2008) 25/09/2006 Adamed SP ZOO. Clopidogrel 5- sulfosalicylic acid forms I and II
WO2008046792A1 (Majka, Sawicki, 
Trizepal, 2008)
17/10/2006 Adamed SP ZOO. Racemic clopidogrel polymorph
WO2008108742A2 (Veverka et al., 
2008)
08/03/2007 Krka Tovarna Zdravil 
DD novo.
Clopidogrel hydrobromide forms α, β, and γ; 
Amorphous clopidogrel hydrobromide
KR20090004268A (Ho et al., 2009a) 06/07/2007 SK Chemicals CO Ltd.  No data retrieved
KR20090004269A (Ho et al., 2009b) 06/07/2007 SK Chemicals CO Ltd  No data retrieved
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development of new crystalline salts and polymorphic 
forms as alternatives to clopidogrel bisulfate for use in 
future medicines. In summary: clopidogrel bisulfate 
(Bousquet, Castro, 1999; Lifshitz-Liron et al., 2003; 
Narasa, et al., 2004), clopidogrel hydrochloride (Kótay 
Nagy et al., 2003); Gangakhed-Kar, 2007), clopidogrel 
hydrobromide (Arul et al., 2005; Hajicek, Pihera, 
Stepankova, 2005a,b; Finkelstein, Aronhime, Tessler, 
2006; Weber, Levis, Ly, 2005; Jetti, Griesser, 2006; 
Lorimer, Ng, 2005a; Veverka et al., 2008), clopidogrel 
hydrobromide hydrate (Finkelstein, Aronhime, Tessler, 
2006), clopidogrel hydrobromide monohydrate (Jetti, 
Griesser, 2006), clopidogrel napsylate (Weber, Levis, Ly, 
2005), clopidogrel camphor-10-sulfonate (Simonic et al., 
2008), naphthalene 1,5- disulfonate of clopidogrel and its 
hydrates/solvates (Lorimer, Ng, 2005b), sulfosalicylate 
of clopidogrel (Majka et al., 2008), Monohydrate racemic 
Clopidogrel (Ho et al., 2009a,b), racemate of clopidogrel 
free base (Majka, Sawcki, Trzepalka, 2008), and further 
applications of different amorphous clopidogrel salt forms 
(Rao, Kankan, 2004; Piechaczek et al., 2004; Gangakhed-
Kar, 2007; Veverka et al., 2008); Parthasaradhi et al., 
2004; Kaznanov, Veverkova, Veverka, 2005) and mixtures 
of amorphous forms with polymorphic forms (Lohray et 
al., 2004). Only 02 patent applications were filed in Brazil, 
the equivalent to WO9965915 (PI9911219, Bousquet, 
Castro, Saint-Germain, 2001) and WO2005103058 
(PI0509997, Lorimer, Ng, 2005a), both matters patented 
by Sanofi-Aventis.
The results show that clopidogrel polymorphs have 
overlapping nomenclatures and likely, redundancies in 
their subject matter. This fact is due to the difficulty of 
establishing consistent nomenclature for polymorphic 
forms in the current literature. Furthermore, as a patent 
application is published only 18 months after filing, the 
nomenclature used by the inventors tends to overlap. Thus, 
it is extremely important that the results of crystalline phase 
analysis and physico-chemical properties of crystalline 
forms are included. The technical patent examination by 
the patent office can be clear and fast only with reliable 
subject matter disclosed in a patent application. 
Assessment of analytical techniques for 
characterizing crystalline/polymorphic forms in 
clopidogrel patent applications 
A total of 18 of the 24 patent applications for 
cclopidogrel were evaluated (amorphous patent 
applications were excluded). In Figure 3, the results 
regarding the number of times the analytical techniques 
were used in the patents of the clopidogrel forms are 
plotted. PXRD was found to be the most widely used 
technique for the characterization of crystalline forms, 
followed by thermal and spectrometric techniques. 
HPLC remains the standard technique used to evaluate 
the chemical purity of the crystallized drugs; however, 
elementary analysis and gas chromatography (GC) were 
also employed. SCXRD was found not to be frequently 
used - only in WO9965915 (Bousquet, Castro, 1999) 
and EP1674468 (Jetti, Griesser, 2006). The limited 
use of SCXRD may be explained by the experimental 
difficulty in obtaining single crystals as well as the limited 
availability of this equipment.
The number of techniques used to characterize 
crystalline forms of clopidogrel in patent applications is 
summarized in Figure 4. The results indicated that only 03 
patent applications used more than two characterization 
techniques (one of them being PXRD) and analyzed 
the chemical purity of the samples. Of the 07 patent 
applications that demonstrated the use of more than two 
characterization techniques without purity analysis, two 
FIGURE 2 – Nationality of applicants in patent applications for 
clopidogrel crystalline forms.
FIGURE 3 – Analytical techniques for characterization of the 
crystalline phase present in clopidogrel patent applications.
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used SCXRD (which presumes a pure single crystal). 
Therefore, it appears that only 05 Clopidogrel patent 
applications fulfilled all the proposed guidelines set out 
by the INPI regarding characterization of polymorphic 
forms. Patent application PI9911219 is in accordance 
with the INPI proposed guidelines – it used SCXRD for 
Bisulfate clopidogrel form II characterization whereas 
patent application PI0509997 is not in accordance with 
INPI proposed guidelines. This latter application disclosed 
three techniques for characterization of polymorphic forms 
of clopidogrel hydrobromide (PXRD, FTIR and melt 
point) but no purity analysis was conducted.
The main reasons underlying the non-adequacy of 
patent applications with regards to the proposed INPI 
guidelines were: (i) insufficient number of characterization 
techniques (8 patent applications); and (ii) absence 
of chemical purity analysis of the samples (7 patent 
applications), but also the fact that when PXRD was used, 
indexation was lacking (angles of reflection, interplanar 
spacings and relative intensity of peaks were not disclosed 
in the text) as well as omission of the unit cell parameters 
(in cases of PXRD use with indexation). All of these 
crucial factors need to be present in order to ensure the 
adequacy of patent applications.
Preparation of Clopidogrel bisulfate form II 
bisulfate based on data provided in patent 
application PI9911219
Characterization of clopidogrel bisulfate forms I and II
Commercial clopidogrel bisulfate samples were 
purchased and characterized in order to compare them 
with prior art. The chemical purity of both forms was 
measured by HPLC and found to be 99.7% and 99.9% 
for forms I and II, respectively. The retention times were 
found to be 6.3 and 6.7 min for the two forms, respectively. 
Characterization of the crystalline phase for both isoforms 
was accomplished using PXRD, IR and DSC. For the 
clopidogrel free base, a content of 99.9% was obtained by 
HPLC. Figures 5-7 shows the IR, DSC and PXRD spectra 
for the commercial clopidogrel bisulfate samples tested.
The characterization results of the commercial 
grade clopidogrel bisulfate samples are summarized in 
Table 4. These results show that the experimental data of 
IR and DSC are consistent with that found in the literature 
(Bousquet, Castro, Saint-Germain, 2001; Koradia, 
Chawla, Bansal, 2004).
Some discrepancies were found at a specific peak 
in form I between the matters reported in the patent 
application versus experimental results and literature data. 
In the commercial samples and the product analyzed by 
Koradia (2004), the peak with the greatest intensity was 
23.00° and 23.15°, respectively, while in PI9911219 it 
was around 9.24°. There were also diffraction peaks at 
around 9.26° in the diffractogram patterns of the tested 
commercial samples and in the material obtained from 
Koradia (2004). However, these diffraction peaks had 
FIGURE 4 – Number of techniques present in patent applications for clopidogrel crystalline forms.
FIGURE 5 – Infrared spectra of clopidogrel bisulfate form I 
(bottom) and form II (top).
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TABLE IV – Experimental data of IR, PXRD and DSC for the polymorphic forms I and II of clopidogrel bisulfate
Clopidogrel 
bisulfate 
PXRD (characteristic peaks, 2θ) IV (characteristic 
bands - cm-1)
DSC (0C)
Commercial 
Samples
Form I 9.26°, 14.39°, 23.15° 2987; 1753; 1222; 1175 
and 841
184.0
Form II 8.91°, 21.69° and 23.00° 2551; 1753; 1497; 1189 
and 1029
178.3
Koradia, Chawla, 
Bansal, 2004
Form I 9.26°, 14.39°, 23.15° 2987; 1175; 841 181-190, endothermic 
peak at 186
Form II 8.91°, 12.44°, 21.69°, 23.00° 1497; 1189; 1029 177-182, endothermic 
peak at 179
PI9911219 
(Bousquet, Castro, 
Saint-Germain, 
2001) 
Form I 9.24°, 10.93°, 18.73°, 20.96°,  
23.74°, 23.94°, 26.22° (calculated 
from Bragg’s Law: λ =2dsenθ)
2987, 1753, 1222, 1175, 
841
181.2
Form II 12.99°, 13.74°, 15.80°, 17.92°, 
22.03°, 24.34°, 25.36° (calculated 
from Bragg’s Law: λ =2dsenθ)
2551, 1753, 1497, 1189, 
1029
176
less intensity in the diffractogram pattern of PI9911219 
(Figure 7). The diffraction pattern obtained for form I of 
Clopidogrel bisulfate in the IUCr online database was 
also very similar to the tested commercial samples and 
those obtained from Koradia (Chernyshev et al., 2010). 
This may be attributed to the preferred orientation of 
crystallites in the samples. However, an additional peak 
of great intensity in a diffraction pattern suggests the 
presence of sample impurities or mixtures of polymorphs. 
These results underscore the importance of the physico-
chemical characterization of crystalline forms using a 
multi-analytical approach and at best, the assessment 
of crystallographic purity (phase purity). This finding 
reinforces the relevance of the proposal introduced by 
the INPI.
Attempts to reproduce the crystallization process of 
form II from the description of the process provided in the 
PI9911219 patent application have met with failure. The 
experimental procedure was conducted as follows: 4.42 
g of S - clopidogrel free base was dissolved in 20 mL of 
acetone. Argon was bubbled into this solution and 1.68 g 
was added to 80% aqueous H2SO4 while maintaining the 
temperature below 20 oC. Subsequently, 12 ml of acetone 
was evaporated under reduced pressure conditions. No 
changes were observed in the appearance of the solution 
or profile analysis by thin layer chromatography. The 
mixture was cooled as described in the patent document 
and maintained under argon at the same temperature for 
48 h. As expected, form I did not undergo precipitation, 
therefore a new partial evaporation of acetone was 
conducted and the resultant solution refrigerated for more 
FIGURE 6 – DSC thermograms for forms I (top) and II (bottom) 
of clopidogrel bisulfate.
than 4 months. Even after this period, no precipitation was 
observed with either clopidogrel bisulfate isoform.
In addition, the use of 96% aqueous H2SO4 did not 
lead to precipitation from the acetone solution at different 
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concentrations while being cooled. Use of excess 96% 
aqueous H2SO4 resulted in an intense blackening of 
the reactional medium. The crystals precipitated after 
cooling for 48 hours. However, this was a deviation from 
the procedure described in the patent document. Further 
studies will be conducted using the described procedures 
to obtain both crystalline forms of clopidogrel bisulfate.
DISCUSSION
The pharmaceutical industry has been described in 
the literature as a major user of the patent system. Thus, the 
patent is the instrument of choice used by pharmaceutical 
companies to protect their inventions from exploitation 
by others. Therefore, since TRIPS does not exclude 
polymorphs as patentable matter, different countries are 
free to create technical mechanisms that support patent 
examinations by the patent office.
The global pharmaceutical market can be considered 
an oligopoly since mergers of large transnational 
pharmaceutical companies create an extremely competitive 
market. In 2000, the ten largest pharmaceutical companies 
held almost 46% of the market (Fardelone, Branchi, 2006). 
In this scenario, it is evident that subject matter claimed in 
pharmaceutical patents is inherently complex. Incremental 
innovation provides abundant material for litigation 
between innovative pharmaceutical corporations and 
generic manufacturers. Litigation represents a strategic 
method for companies to obtain indirect extensions of a 
monopoly of earlier molecule patents whose expiration is 
imminent (“evergreening”). Such litigation proceedings 
are detrimental to the entry of generic drugs onto the 
market, due to the temporal aspects of the judicial process 
itself and they also create market uncertainty. This theme 
has been extensively discussed in the literature (Plaza 
De Avila, 2007; Mitsuuchi, 2009; Correa, 2006; Burdon, 
Sloper, 2003; Roox et al., 2008; Bernstein, 2002).
In general, the Brazilian LPI does not exclude 
patentability of crystalline/polymorph forms of drugs. 
More recently, the proposed guideline set out by the INPI 
is a first attempt to harmonize the internal procedures for 
evaluating the patentability of polymorphic forms in the 
pharmaceutical area. Upon evaluation of the proposed 
INPI guidelines, it becomes evident that emphasis has 
FIGURE 7 – PXRD patterns for form I of clopidogrel bisulfate: a) commercial samples; b) adapted from Koradia, Chawla, Bansal, 
2004, c) adapted from PI9911219 – (Bousquet, Castro, Saint-Germain, 2001) and d) adapted from the IUCr database (Chernyshev 
et al., 2010).
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been placed on the importance of physicochemical 
characterization of polymorphs in patent applications 
to assess whether they meet the patent requirements 
of being novel. Therefore, being novel is an objective 
requirement and stipulates that patents should not 
be granted to applications with dubious matter and 
insufficient information. It is important that the claimed 
matter can be differentiated from the state of the art.
The present study showed that about 70% of patent 
applications of clopidogrel crystalline forms do not have 
sufficient data for the appropriate characterization of 
newly developed polymorphic forms set against the state 
of the art. This is troubling since examination of patent 
applications by patent examiners from the INPI depends 
entirely on the matter disclosed in the patent application. 
Furthermore, the results also showed that SCXRD is not 
commonly used in patent applications. Another finding 
was the marked absence of the experimental analysis of 
chemical purity of the samples in patent applications. 
None of the patent applications that used PXRD provided 
all the indexation parameters established in the proposed 
INPI guidelines (see second provision of proposed 
guideline). Finally, PXRD is generally considered the 
definitive technique for crystal characterization. Notably, 
there is no data in the scientific literature that establishes 
a minimum number of diffraction peaks in the diffraction 
pattern (INPI guidelines require at least 20 diffraction 
peaks). Thus, we suggest that this specific criterion 
(presence of 20 diffraction peaks) is not essential for the 
characterization of crystalline/polymorphic forms of drugs 
since the number of diffraction peaks are proportional to 
the arrangements found in a crystal lattice.
At the same time, we have experimentally 
demonstrated the use of various analytical techniques, as 
described in the proposed INPI guidelines and confirmed 
that they are necessary for efficient characterization of 
clopidogrel isoforms. We state that patent applications of 
crystalline forms of drugs should contain an experimental 
procedure to assess the crystallographic purity (phase 
purity) of an isoform that is not the first (as is the case 
for form II of clopidogrel bisulfate). Furthermore, 
it  was experimentally shown that the procedure 
specifications of patent application PI9911219 were 
irreproducible. Consequently, it was not possible to 
retrieve these polymorphic forms by crystallization of 
Form II of clopidogrel bisulfate. Although these results 
are preliminary and require improved experimental 
procedures, this finding suggests that patent applications 
of polymorphic forms do not provide sufficient disclosure 
for reproduction by those skilled in the art.
The data presented in this work demonstrates 
that preparation of the INPI Proposed Guidelines for 
Examination of Patent Applications for New Polymorphic 
Forms is well founded in its design and rationale, 
since patent applications in the pharmaceutical field 
do not always contain sufficient technical elements to 
characterize the various claimed crystalline/polymorphic 
forms. It is known that a proper patent examination should 
be conducted in the shortest time possible, while removing 
the expectation of rights that occurs during the patent 
application filing process. This can lead to a reduction 
in litigation by some applicants who end up involved in 
potential “evergreening” cases. Thus, the initiative taken 
by the INPI included the devising of rigorous patent exam 
guidelines that are essential to curb the culture where 
“poorly drafted patent applications” are often accepted by 
the current patent system.
The advent of small biotechnology companies is 
changing the scenario in which pharmaceutical innovation 
was hitherto restricted to a small number of large 
corporations. The Brazilian government should consider 
growth and development of the pharmaceutical area in 
its strategic plans. Brazil has national pharmaceutical 
companies, which invest in incremental innovation as 
an important source of economic and technological 
development (Bastos, 2005; Shadlen, 2011; Lourenço et 
al., 2010). The fact that there have been no applications 
from Brazilian pharmaceutical companies for clopidogrel 
polymorphs makes it clear that they should consider 
incremental innovations in the pharmaceutical area as a 
viable strategy for pharmaceutical industry growth and 
further reinforces the importance of this topic.
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